MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).-Reference-Cited by-同舟云学术

MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).

Published:2018-05-20 Issue:15_suppl Volume:36 Page:TPS9105-TPS9105
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Johnson Melissa Lynne¹,Solomon Benjamin J.²,Awad Mark M.³,Cho Byoung Chul⁴,Gainor Justin F.⁵,Goldberg Sarah B.⁶,Keam Bhumsuk⁷,Lee Dae Ho⁸,Huang Chen⁹,Helms Hans-Joachim¹⁰,Barak Hila¹¹,Fasso Marcella¹¹,Bleul Conrad¹⁰,Cha Edward¹¹,Rizvi Naiyer A.¹²

Affiliation:

1. Sarah Cannon Research Institute, Nashville, TN;

2. Peter MacCallum Cancer Centre, Melbourne, Australia;

3. Dana-Farber Cancer Institute, Boston, MA;

4. Yonsei Cancer Center, Seoul, Republic of Korea;

5. Massachusetts General Hospital, Boston, MA;

6. Yale Cancer Center, New Haven, CT;

7. Seoul National University Hospital - Cancer Research Institute (CRI), Seoul, Republic of Korea;

8. Asan Medical Center, University of Ulsan College of Medicine Seoul, Seoul, Republic of Korea;

9. F. Hoffmann-La Roche Ltd., Shanghai, China;

10. F. Hoffmann-La Roche Ltd., Basel, Switzerland;

11. Genentech, Inc., South San Francisco, CA;